title: Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.
abstract: Therapeutics developed and sold as racemates can exhibit a limited therapeutic index because of side effects resulting from the undesired enantiomer (distomer) and/or its metabolites, which at times, forces researchers to abandon valuable scaffolds. Therefore, most chiral drugs are developed as single enantiomers. Unfortunately, the development of some chirally pure drug molecules is hampered by rapid in vivo racemization. The class of compounds known as immunomodulatory drugs derived from thalidomide is developed and sold as racemates because of racemization at the chiral center of the 3-aminoglutarimide moiety. Herein, we show that replacement of the exchangeable hydrogen at the chiral center with deuterium allows the stabilization and testing of individual enantiomers for two thalidomide analogs, including CC-122, a compound currently in human clinical trials for hematological cancers and solid tumors. Using "deuterium-enabled chiral switching" (DECS), in vitro antiinflammatory differences of up to 20-fold are observed between the deuterium-stabilized enantiomers. In vivo, the exposure is dramatically increased for each enantiomer while they retain similar pharmacokinetics. Furthermore, the single deuterated enantiomers related to CC-122 exhibit profoundly different in vivo responses in an NCI-H929 myeloma xenograft model. The (-)-deuterated enantiomer is antitumorigenic, whereas the (+)-deuterated enantiomer has little to no effect on tumor growth. The ability to stabilize and differentiate enantiomers by DECS opens up a vast window of opportunity to characterize the class effects of thalidomide analogs and improve on the therapeutic promise of other racemic compounds, including the development of safer therapeutics and the discovery of new mechanisms and clinical applications for existing therapeutics.
authors.affiliation: DeuteRx LLC, Andover, MA 01810; and.
authors.forename: Vincent
authors.initials: V
authors.lastname: Jacques
authors.affiliation: DeuteRx LLC, Andover, MA 01810; and.
authors.forename: Anthony W
authors.initials: AW
authors.lastname: Czarnik
authors.affiliation: Kalexsyn Inc., Kalamazoo, MI 49008.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Judge
authors.affiliation: DeuteRx LLC, Andover, MA 01810; and.
authors.forename: Lex H T
authors.initials: LH
authors.lastname: Van der Ploeg
authors.affiliation: DeuteRx LLC, Andover, MA 01810; and sdewitt@deuterx.com.
authors.forename: Sheila H
authors.initials: SH
authors.lastname: DeWitt
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry*; D000970:Antineoplastic Agents / Q000737:chemistry*; D045744:Cell Line, Tumor; D002470:Cell Survival; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D051379:Mice; D016513:Mice, SCID; D008956:Models, Chemical; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010881:Piperidones / Q000737:chemistry*; D052999:Quinazolinones / Q000737:chemistry*; D013237:Stereoisomerism; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000737:chemistry; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: C000602306:3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D010881:Piperidones; D052999:Quinazolinones; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide
keywords: CC-122; cancer; deuterium; enantiomer; thalidomide